medigraphic.com
ISSN 0210-5187 (Electronic)

2018, Number 3

<< Back Next >>

Med Cutan Iber Lat Am 2018; 46 (3)

Pityriasis versicolor: an update

Ramírez-Godínez JB, Carreño-Gayosso EA, Soto-Ortiz JA, Tarango-Martínez VM, Mayorga-Rodríguez JA

Language: Spanish
References: 71
Page: 166-175
PDF size: 494.87 Kb.


ABSTRACT

Pityriasis versicolor is one of the most frequent fungal cutaneous infections; caused by a yeast of the genus Malassezia, it is more prevalent in countries with tropical and subtropical climate. It is essential for dermatologists to recognize it and offer an appropriate treatment. We present an update on the epidemiology, clinical appearance, etiology and the most used treatments in this disease.


REFERENCES

  1. Sánchez AL, Fernández RF, Moreno G, Arenas R. Pitiriasis versicolor y Malassezia spp: una revisión. Dermatol CMQ. 2014; 12: 52-57.

  2. Padilla MC. Pitiriasis versicolor. Dermatol Rev Mex. 2005; 49: 157-167.

  3. Giusiano GE. Malassezia. Estado del conocimiento y perspectivas en su estudio. Revista Argentina de Microbiología. 2006; 38: 41-48.

  4. Guillot J, Guého E, Lesourd M, Midgley G, Chevrier G, Dupont B. Identification of Malassezia species. A practical approach. J Mycol Med. 1996; 6: 103-110.

  5. Ashbee HR. Update on the genus Malassezia. Medical Mycology. 2007; 45: 287-303.

  6. Grice EA, Dawson TL. Host-microbe interactions: Malassezia and human skin. Curr Opinion Microbiol. 2017; 40: 81-87.

  7. Ben Salah S, Makni F, Marrakchi S, Sellami H, Cheikhrouhou F, Bouassida S et al. Identification of Malassezia species from Tunisian patients with pityriasis versicolor and normal subjects. Mycoses. 2005; 48: 242-245.

  8. Ochoa MM. Estudio de las especies de Malassezia, relacionadas con la patología cutánea, Pitiriasis Versicolor en Panamá [Tesis doctoral]. Panamá: Instituto de Biotecnología, Departamento de Microbiología, Universidad de Granada y Universidad de Panamá; 2006.

  9. Prohic A, Ozegovic L. Malassezia species isolated from lesional and non-lesional skin in patients with pityriasis versicolor. Mycoses. 2006; 50: 58-63.

  10. Krisanty RI, Bramono K, Made Wisnu I. Identification of Malassezia species from pityriasis versicolor in Indonesia and its relationship with clinical characteristics. Mycoses. 2008; 52: 257-262.

  11. Karakas M, Turac-Bicer A, Ilkit M, Durdu M, Seydaoglu G. Epidemiology of pityriasis versicolor in Adana, Turkey. J Dermatol. 2009; 36: 377-382.

  12. Tango E, Vargas J. Caracterización fenotípica de las especies del género Malassezia aisladas de pacientes con pitiriasis versicolor en Santa Cruz-Bolivia. Rev. de Enfermedades Infecciosas y Tropicales. 2009; 1: 33-36.

  13. Rasi A, Naderi R, Behzadi AH, Falahati M, Farehyar S, Honarbakhsh Y et al. Malassezia yeast species isolated from Iranian patients with pityriasis versicolor in a prospective study. Mycoses. 2010; 53: 350-355.

  14. Giusiano G, Sosa Mde L, Rojas F, Vanacore ST, Mangiaterra M. Prevalence of Malassezia species in pityriasis versicolor lesions in northeast Argentina. Rev Iberoam Micol. 2010; 27: 71-74.

  15. Ramadán S, Sortino M, Bulacio L, Marozzi ML, López C, Ramos L. Prevalence of Malassezia species in patients with pityriasis versicolor in Rosario, Argentina. Rev Iberoam Micol. 2012; 29: 14-19.

  16. Archana BR, Beena PM, Kumar S. Study of the distribution of Malassezia species in patients with pityriasis versicolor in Kolar región, Karnataka. Indian J Dermatol. 2015; 60: 321.

  17. Talaee R, Katiraee F, Ghaderi M, Erami M, Kazemi Alavi A, Nazeri M. Molecular identification and prevalence of Malassezia species in pityriasis versicolor patients from Kashan, Iran. Jundishapur J Microbiol. 2014; 7: e11561.

  18. Rodoplu G, Saracli MA, Gümral R, Taner Yildiran S. Distribution of Malassezia species in patients with pityriasis versicolor in Turkey. J Mycol Med. 2014; 24: 117-123.

  19. Ahmed SMA, Roy CK, Jaigirdar QH, Khan RR, Nigar I, Saleh AA. Identification of Malassezia species from suspected pityriasis (versicolor) patients. Bangladesh J Med Microbiol. 2015; 9: 17-19.

  20. Sharma A, Rabha D, Choraria S, Hazarika D, Ahmed G, Hazarika NK. Clinicomycological profile of pityriasis versicolor in Assam. Indian J Pathol Microbiol. 2016; 59: 159-165.

  21. Elshabrawy WO, Saudy N, Sallam M. Molecular and phenotypic identification and speciation of Malassezia yeast isolated from Egyptian patients with pityriasis versicolor. J Clin Diagn Res. 2017; 11: DC12-DC17.

  22. Hernández F, Méndez LJ, Bazán E, Arévalo A, Valera A, López R. Especies de Malassezia asociadas a diversas dermatosis y a piel sana en población Mexicana. Rev Iberoam Micol. 2003; 20: 141-144.

  23. Crespo Erchiga V, Ojeda Martos A, Vera Casaño A, Crespo Erchiga A, Sanchez Fajardo F. Malassezia globosa as the causative agent of pityriasis versicolor. Br J Dermatol. 2000; 143: 799-803.

  24. Gupta AK, Khohli Y, Faergemann J, Summerbell RC. Epidemiology of Malassezia yeasts associated with pityriasis versicolor in Ontario, Canadá. Medical Mycology. 2001; 39: 199-206.

  25. Gaitanis G, Velegraki A, Alexopoulos ES, Chasapi V, Tsigonia A, Katsambas A. Distribution of Malassezia species in pityriasis versicolor and seborrhoeic dermatitis in Greece. Typing of the major pityriasis versicolor isolate M. globosa. Br J Dermatol. 2006; 154: 854-859.

  26. Petry V, Tanhausen F, Weiss L, Milan T, Mezzari A, Weber MB. Identification of Malassezia yeast species isolated from patients with pityriasis versicolor. An Bras Dermatol. 2011; 86: 803-806.

  27. Lyakhovitsky A, Shemer A, Amiachai B. Molecular analysis of Malassezia species isolated from Israeli patients with pityriasis versicolor. Int J Dermatol. 2013; 52: 231-233.

  28. Ibekwe PU, Ogunbiyi AO, Besch R, Ruzicka T, Sárdy M. The spectrum of Malassezia species isolated from students with pityriasis versicolor in Nigeria. Mycoses. 2015; 58: 203-208.

  29. Xie Z, Ran Y, Zhang H, Zhang M, Wan H, Li C. An analysis of the Malassezia species distribution in the skin of patients with pityriasis versicolor in Chengdu, China. Scientific World Journal. 2014: 182596.

  30. Velegraki A, Cafarchia C, Gaitanis G, Iatta R, Boekhout T. Malassezia infections in humans and animals: pathophysiology, detection, and treatment. PLoS Pathog. 2015; 11: e1004523.

  31. Gaitanis G, Velegraki A, Mayser P, Bassukas ID. Skin diseases associated with Malassezia yeasts: facts and controversies. Clin Dermatol. 2013; 31: 455-463.

  32. Zinkeviciene A, Norkunas V, Citavicius D. Atypical non-lipid-dependent strains of Malassezia furfur. Cent Eur J Biol. 2012; 7: 241-249.

  33. Puig L, Bragulat MR, Castellá G, Cabañes J. Characterization of the species Malassezia pachydermatis and re-evaluation of its lipid dependence using a synthetic agar medium. PLoS One. 2017; 12: e179148.

  34. Shibata N, Saitoh T, Tadokoro Y, Okawa Y. The cell wall galactomannan antigen from Malassezia furfur and Malassezia pachydermatis contains ?-1,6-linked linear galactofuranosyl residues and its detection has diagnostic potential. Microbiology. 2009; 155: 3420-3429.

  35. Stalhberger T, Simenel C, Clavaud C, Eijsink VG, Jourdain R, Delepierre M et al. Chemical organization of the cell wall polysaccharide core of Malassezia restricta. J Biological Chemistry. 2014; 289: 12647-12656.

  36. Angiolella L, Leone C, Rojas F, Mussin J, Sosa MA, Giusiano G. Biofilm, adherence, and hydrophobicity as virulence factors in Malassezia furfur. Medical Mycology. 2017; 0: 1-7.

  37. Coutinho SD, Paula CR. Proteinase, phospholipase, hyaluronidase and chondroitin- sulphatase production by Malassezia pachydermatis. Medical Mycology. 2000; 38: 73-76.

  38. Pedrosa AF, Lisboa C, Rodriges AG. Malassezia infections: A medical conundrum. J Am Acad Dermatol. 2014; 71: 170-176.

  39. Ashbee HR. Recent developments in the immunology and biology of Malassezia species. FEMS Immunol Med Microbiol. 2006; 47: 14-23.

  40. Medina DE. Dermatitis seborreica: una revisión. Dermatología CMQ. 2014; 12: 135-141.

  41. Levy JM, Magro C. Atrophying pityriasis versicolor as an idiosyncratic T cell-mediated response to Malassezia: a case series. J Am Acad Dermatol. 2017; 76: 730-735.

  42. Krämer HJ, Podobinska M, Bartsch A, Battmann A, Thoma W, Bernd A et al. Malassezin, a novel agonist of the aryl hydrocarbon receptor from the yeast Malassezia furfur, induces apoptosis in primary human melanocytes. Chem Bio Chem. 2005; 6: 860-865.

  43. Nazzaro-Porro M, Passi S. Identification of tyrosinase inhibitors in cultures of Pityrosporum. J Invest Dermatol. 1978; 71: 205-208.

  44. Chang TS. Natural melanogenesis inhibitors acting through the down-regulation of tyrosinase activity. Materials. 2012; 5: 1661-1665.

  45. Galadari I, El Komy M, Mousa A, Hashimoto K, Mehregan AH. Tinea versicolor; histologic and ultrastructural investigation of pigmentary changes. Int J Dermatol. 1992; 31: 253-256.

  46. Padilla C, Rodríguez M, Medina D, Gutiérrez SC, Mendoza L, Ramos A. Pitiriasis versicolor. Presentación de tres casos. Rev Cent Dermatol Pascua. 2004; 13: 49-55.

  47. Crespo-Erchiga V, Gómez-Moyano E, Crespo M. La pitiriasis versicolor y las levaduras del género Malassezia. Actas Dermosifiliogr. 2008; 99: 764-771.

  48. Haiduk J, Treudler R, Ziemer M. Atrophying tinea versicolor with epidermal atrophy. J Ger Society Dermatol. 2016; 1407: 740-742.

  49. Gaitanis G, Magiatis P, Hantschke M, Bassukas ID, Velegraki A. The Malassezia genus in skin and systemic diseases. Clin Microbiol Reviews. 2012; 25: 106-141.

  50. Errichetti E, Stinco G. Dermoscopy in general dermatology: a practical overview. Dermatol Ther. 2016; 6: 471-507.

  51. Zhou H, Tang XH, De Han J, Chen MK. Dermoscopy as an ancillary tool for the diagnosis of pityriasis versicolor. J Am Acad Dermatol. 2015; 73: 205-206.

  52. Gupta AK, Foley KA. Antifungal treatment for pityriasis versicolor. J Fungi. 2015; 1: 13-29.

  53. Gupta AK, Lyons DC. Pityriasis versicolor: an update on pharmacological treatment options. Expert Opin Pharmacother. 2014; 15: 1707-1713.

  54. Gupta AK, Lane D, Paquet M. Systematic review of systemic treatments for tinea versicolor and evidence based dosing regimen recommendations. J Cutan Med Surg. 2013; 2: 1-12.

  55. Hald M, Arendrup MC, Svejgaard EL, Lindskov R, Foged EK, Saunte DM. Evidence-based Danish guidelines for the treatment of Malassezia related skin diseases. Acta Derm Venereol. 2015; 95: 12-19.

  56. Di Fonzo EM, Martini P, Mazzatenta C, Lotti L, Alvino S. Comparative efficacy and tolerability of Ketomousse® (ketoconazole foam 1%) and ketoconazole cream 2% in the treatment of pityriasis versicolor: results of a prospective, multicentre, randomised study. Mycoses. 2008; 51: 532-535.

  57. Shi TW, Zhang JA, Tang YB, Yu HX, Li ZG, Yu JB. A randomized controlled trial of combination treatment with ketoconazole 2% cream and adapalene 0.1% gel in pityriasis versicolor. J Dermatolog Treat. 2015; 26: 143-146.

  58. Shi TW, Ren XK, Yu HX, Tang YB. Roles of adapalene in the treatment of pityriasis versicolor. Dermatology. 2012; 224: 184-188.

  59. Tanenbaum L, Anderson C, Rosenberg MJ, Akers W. 1% sulconazole cream v 2% miconazole cream in the treatment of tinea versicolor: a double-blind, multicenter study. Arch Dermatol. 1984; 120: 216-219.

  60. Dehghan M, Akbari N, Alborzi N, Sadani S, Keshtkar AA. Single-dose oral fluconazole versus topical clotrimazole in patients with pityriasis versicolor: a double-blind randomized controlled trial. J Dermatol. 2010; 37: 699-702.

  61. Kausar S, Shaikh ZI, Malik S, Ahmed N. Comparison of oral itraconazole versus topical clotrimazole in treatment of pityriasis versicolor. Pak Armed Forces Med J. 2017; 67: 458-461.

  62. Budimulja U. One-week terbinafine 1% solution in pityriasis versicolor: twice-daily application is more effective than once-daily. J Dermatolog Treat. 2002; 13: 39-40.

  63. Rad F, Nik-Khoo B, Yaghmaee R, Gharibi F. Terbinafin 1% cream and ketoconazole 2% cream in the treatment of pityriasis versicolor: a randomized comparative clinical trial. Pak J Med Sci. 2014; 30: 1273-1276.

  64. Amer MA, Abdallah MA, Abdel-Aal MA, Abdel-Hamis E, El-Mansy E, El-Tonsy H et al. Fluconazole in the treatment of tinea versicolor. Int J Dermatol. 1997; 36: 938-946.

  65. Montero-Gei F, Robles ME, Suchil P. Fluconazole vs. itraconazole in the treatment of tinea versicolor. Int J Dermatol. 1999; 38: 601-603.

  66. Partap R, Kaur I, Chakrabarti A, Kumar B. Single-dose fluconazole versus itraconazole in Pityriasis versicolor. Dermatology. 2004; 208: 55-59.

  67. Galimberti RL, Villalba I, Galarza S, Raimondi A, Flores V. Itraconazole in pityriasis versicolor: ultrastructural changes in Malassezia furfur produced during treatment. Rev Infect Dis. 1987; 9: 134-138.

  68. Kokturk A, Kaya TI, Ikizoglu G, Bugdayci R, Koca A. Efficacy of three short-term regimens of itraconazole in the treatment of pityriasis versicolor. J Dermatolog Treat. 2002; 13: 185-187.

  69. Faergemann J, Todd G, Pather S, Vawda ZF, Gillies JD, Walford T et al. A double-blind, randomized, placebo-controlled, dose-finding study of oral pramiconazole in the treatment of pityriasis versicolor. J Am Acad Dermatol. 2009; 61: 971-976.

  70. Faergemann J, Gupta AK, Al Mofadi A, Abanami A, Shareaah AA, Marynissen G. Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor. Arch Dermatol. 2002; 138: 69-73.

  71. Hersle K. Selenium sulphide treatment of tinea versicolor. Acta Derm Venereol. 1971; 51: 476-478.




2020     |     www.medigraphic.com